Bioequivalance Famotidine 40 mg.
Conditions
Interventions
Intervention 1: Intervention group 1: One Famotidine 40 mg tablet manufactured by Fatak chemie pars company (Test drug) is administrated to each of 12 healthy volunteer of group 1. Intervention 2: In
Sponsors
Fatak chemie pars Pharmacy
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Healthy liver Healthy kidney Volunteers should not be too fat or too thin and their weight index should be in the appropriate range
Exclusion criteria
Exclusion criteria: Out of age ranges smoking pragnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma concentration changing after administration of Famotidine tablet.Plasma concentration of famotidine at Tmax reaches about 200 ng/mL and its measurement range is from 10ng / mL to 700ng / mL. Timepoint: Initial blood sampling is performed before drug administration to obtain blank plasma chromatogram of each volunteers. Hence the Tmax of Famotidine is between 1 and 3 hours, so it is needed to have 5 blood sampling before Tmax. This period of time is called absorption phase. In the elimination phase (after Tmax) blood sampling carry out each hours. Method of measurement: In this study, the variable is plasma concentration of famotidine. High performance liquid chromatography is used to determine the concentration of famotidine in plasma. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Amir mehdizahed
Ofoqh pharmed labratory
Outcome results
None listed